magistrsko diplomsko delo
Tea Lobe (Author), Rajko Pirnat (Mentor)

Abstract

Trgovanje z zdravili sodi med najbolj regulirano področje v industrijskem sektorju. Temeljno načelo v okviru celotne Evropske unije in Evropskega gospodarskega prostora je, da je lahko zdravilo na trgu le na podlagi dovoljenja za promet. Postopek pridobitve dovoljenja za promet je upravni postopek, kateri se bo uporabil pa je odvisno od tega, kje se bo zdravilo tržilo. Poznamo nacionalni postopek, postopek z medsebojnim priznavanjem, decentraliziran postopek in centraliziran postopek. Cilj, ki ga zakonodaja na področju zdravil zasleduje, je varovanje javnega zdravja. Postopke pridobitve dovoljenja za promet vodijo regulatorni organi. Na ravni Evropske unije je ta organ Evropska agencija za zdravila (skrajšano EMA), v Slovenija pa Javna agencija za zdravila in medicinske pripomočke (skrajšano JAZMP). V farmacevtskem sektorju ločimo dve vrsti podjetij. Podjetja, ki proizvajajo inovativna zdravila in so dejavna predvsem na področju raziskav za nova zdravila ter podjetja, ki proizvajajo generična zdravila, ki so enakovredna inovativnim, vendar precej cenejša. Glede na to, ali se pridobiva dovoljenje za promet z inovativnim zdravilom ali generičnim zdravilom, je prilagojen tudi postopek pridobitve dovoljenja za promet. Pri tem imajo proizvajalci inovativnih zdravil pogosto interes sodelovanja v postopku ali uveljavljanje pravnih sredstev zoper izdano odločbo za generično zdravilo. Ker evropska zakonodaja teh možnosti izrecno nikjer ne navaja, je to področje že večkrat bilo predmet sodnih odločitev, ki pravne praznine na tem področju zapolnjujejo.

Keywords

zdravila;farmacevtski sektor;farmacevtska industrija;promet z zdravili;dovoljenje za promet;dovoljenje za promet z zdravili;inovativna zdravila;generična zdravila;javno zdravje;regulatorni organi;referenčne države;zadevne države;Javna agencija Republike Slovenije za zdravila in medicinske pripomočke;JAZMP;Evropska agencija za zdravila;EMA;medicina in pravo;Slovenija;Evropska unija;magistrske diplomske naloge;

Data

Language: Slovenian
Year of publishing:
Typology: 2.09 - Master's Thesis
Organization: UL PF - Faculty of Law
Publisher: [T. Lobe]
UDC: 3.077.3:615(043.2)
COBISS: 16644945 Link will open in a new window
Views: 848
Downloads: 273
Average score: 0 (0 votes)
Metadata: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Other data

Secondary language: English
Secondary title: Procedural questions of obtaining marketing authorization for medicinal products
Secondary abstract: Trade in medicinal products is one of the most regulated areas in the industrial sector. The fundamental principle throughout the European Union and the European Economic Area is that a medicinal product on the market can only be present based on a marketing authorization. The procedure for getting a marketing authorization is an administrative procedure and which one will be used depends on where the product will be marketed. We know a national procedure, a mutual recognition procedure, a decentralized procedure and a centralized procedure. The objective pursued by the legislation on the field of medicinal products is the protection of public health. The procedures for getting a marketing authorization are managed by the regulatory authorities. At European Union level, the authority is the European Medicines Agency (EMEA), while in Slovenia it is the Agency for Medicinal Products and Medical Devices (JAZMP). There are two types of companies in pharmaceutical sector - companies that produce innovative medicinal products and are mainly active in research for new medicinal products and companies that produce generic medicinal products that are equivalent to innovative but much cheaper because they do not need to carry out expensive researches. Depending on whether they are getting a marketing authorization for an innovative medicinal product or a generic one, the procedure is also adjusted. Innovative medicinal products manufacturers often have an interest in cooperating in the procedure or enforcing the legal assets against the issued order for generic medicinal product. Since European legislation does not explicitly state these options, this area has been repeatedly a subject to judicial decisions that fill legal vacuum in this area.
Secondary keywords: pharmaceutical sector;pharmaceutical industry;medicinal products;marketing authorization;marketing authorization for medicinal products;innovative medicines;generic medicines;public health;regulatory bodies;reference Member States;concerned Member States;Agency for Medicinal Products and Medical Devices of the Republic of Slovenia;JAZMP;European Medicines Agency;EMA;
Type (COBISS): Master's thesis/paper
Study programme: 0
Embargo end date (OpenAIRE): 1970-01-01
Thesis comment: Univ. v Ljubljani, Pravna fak.
Pages: 54 f.
ID: 11061077